Fms like tyrosine Kinase 3 (FLT3), also named as CD135, FLK2, is receptor kinase receptor, expressed on the surface of many hematopoietic progenitor cells. Overactivation of FLT3 due to mutation and overexpression can lead to the development and poor prognosis of Leukemia, the identification of FLT3 as a driver gene has led to the repaid development of anti-AML therapeutics, including Sunitinib, Sorafenib and Quizartinib (AC220).
Ba/F3 cell, a murine interleukin-3 dependent pro-B cell line, is a popular system for exploring both kinases and their inhibitors, because some protein kinases can render the Ba/F3 cells to be depended on the activation of the kinases instead of IL-3 supplement, while their inhibitors can antagonize the kinase-dependent growth effects.